Statement Of Cash Flows [Abstract]

Xbrane Biopharma - Filing #702448

Concept As at
2021-12-31
2021-01-01 to
2021-12-31
As at
2020-12-31
2020-01-01 to
2020-12-31
As at
2019-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Cash flows from (used in) operations
181 195 SEK
219 779 SEK
Cash flows from (used in) operating activities
219 610 SEK
238 407 SEK
Cash flows from (used in) investing activities [abstract]
Purchase of property, plant and equipment, classified as investing activities
27 678 SEK
3 855 SEK
Purchase of intangible assets, classified as investing activities
49 672 SEK
Cash flows from (used in) investing activities
77 350 SEK
3 855 SEK
Cash flows from (used in) financing activities [abstract]
Proceeds from changes in ownership interests in subsidiaries that do not result in loss of control
3,000 SEK
Proceeds from issuing shares
380 870 SEK
346 444 SEK
Repayments of borrowings, classified as financing activities
12,000 SEK
Payments of lease liabilities, classified as financing activities
7 273 SEK
3 127 SEK
Cash flows from (used in) financing activities
349 365 SEK
322 724 SEK
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
52 406 SEK
80 461 SEK
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
1 393 SEK
1 520 SEK
Cash and cash equivalents
295 180 SEK
243 139 SEK
164 197 SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.